Highlight 5 in breast cancer
Dr. Guilherme Nader Marta, from the Hôpital Universitaire de Bruxelles, Institut Jules Bordet, recently shared his insights on the most noteworthy presentations from the poster discussion session on metastatic breast cancer.
One of the studies presented was an exploratory biomarker analysis of the DESTINY-Breast04 study, which compared trastuzumab deruxtecan with physician’s choice treatment in patients with HER2-low, hormone receptor-positive unresectable and/or metastatic breast cancer.
Another study from France reported the efficacy of tucatinib + trastuzumab + capecitabine after trastuzumab-deruxtecan exposure in HER2-positive metastatic breast cancer. The LEONARDE study showcased the effectiveness of Lerociclib, a new oral CDK4/6 inhibitor.
Lastly, the PALOMAGE study presented efficacy data from the first-line systemic treatment with palbociclib for women aged 70 years and above, who have hormone receptor-positive advanced breast cancer.
With the educational support of:
